Proteomics offers insight into studies of human disease including the opportunity
to: define underlying mechanisms of disease; determine disease susceptibility; stage
disease and monitor its progression; assess susceptibility to, or identify exacerbation;
select treatment and monitor response to it; and to assist in the performance of clinical
trials. Although the common perception is that proteomics is primarily a tool for
identifying biomarkers, this view sells the significant potential of this evolving
technology short of its full potential.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in PediatricsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Progress with gene product mapping of the mollicutes: Mycoplasma genitalium.Electrophoresis. 1995; 16: 1090-1094
- National Heart, Lung, and Blood Institute Clinical Proteomics Working Group report.Circulation. 2004; 109: 1697-1703
- Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer.J Natl Cancer Inst. 2005; 97: 307-309
- Lessons from controversy: ovarian cancer screening and serum proteomics.J Natl Cancer Inst. 2005; 97: 315-319
- Distilling cancer biomarkers from the serum peptidome: high technology reading of tea leaves or an insight to clinical systems biology?.J Clin Oncol. 2005; 23: 4835-4837
- The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales.Brief Funct Genomic Proteomic. 2005; 3: 322-331
- The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.Clin Chem. 2006; 52: 1223-1237
- Proteomics: from basic research to diagnostic application. A review of requirements and needs.J Proteome Res. 2005; 4: 1086-1097
- Current developments in SELDI affinity technology.Mass Spectrom Rev. 2004; 23: 34-44
- SELDI protein chip MS: a platform for biomarker discovery and cancer diagnosis.Expert Rev Mol Diagn. 2002; 2: 549-563
- Proteomic patterns: their potential for disease diagnosis.Mol Cell Endocrinol. 2005; 230: 95-106
- OvaCheck: let's not dismiss the concept.Nature. 2004; 430: 611
- Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models.Anticancer Res. 2006; 26: 1983-1988
- Identification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling.Clin Chem. 2006; 52: 1501-1509
- Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma.Proteomics. 2006; 6: 3426-3435
- Protein chip array profiling analysis of sera from neuroblastoma patients.Cancer Lett. 2005; 228: 91-96
- Serological protein profiling of neuroblastoma by ProteinChip SELDI-TOF technology.J Cell Biochem. 2005; 95: 165-172
- Serum proteomic patterns associated with sleep-disordered breathing in children.Pediatr Res. 2006; 59: 466-470
- Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy.Arthritis Res Ther. 2005; 7: R746-R755
- Protein stains for proteomic applications: which, when, why?.Proteomics. 2006; 6: 5385-5408
- Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases.Proc Natl Acad Sci U S A. 1993; 90: 5011-5015
- Protein identification by mass profile fingerprinting.Biochem Biophys Res Commun. 1993; 195: 58-64
- Use of mass spectrometric molecular weight information to identify proteins in sequence databases.Biol Mass Spectrom. 1993; 22: 338-345
- Peptide mass maps: a highly informative approach to protein identification.Anal Biochem. 1993; 214: 397-408
- Protein identification methods in proteomics.Electrophoresis. 2000; 21: 1145-1154
- A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard.Proteomics. 2003; 3: 36-44
- All about DIGE: quantification technology for differential-display 2D gel proteomics.Expert Rev Proteomics. 2004; 1: 401-409
- Difference gel electrophoresis: a single gel method for detecting changes in protein extracts.Electrophoresis. 1997; 18: 2071-2077
- Two-dimensional gel electrophoresis as tool for proteomics studies in combination with protein identification by mass spectrometry.Proteomics. 2006; 6: 4688-4703
- Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains.Proteomics. 2002; 2: 3-10
- The application of DIGE-based proteomics to renal physiology.Nephron Physiol. 2006; 104: p61-p72
- The proteomics of sickle cell disease: profiling of erythrocyte membrane proteins by 2D-DIGE and tandem mass spectrometry.Exp Biol Med (Maywood). 2005; 230: 787-792
- Proteomics-based strategy to identify biomarkers and pharmacological targets in leukemias with t(4;11) translocations.J Proteome Res. 2006; 5: 2743-2753
- Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.Clin Appl Thromb Hemost. 2006; 12: 397-420
- Exploring the context of the lung proteome within the airway mucosa following allergen challenge.J Proteome Res. 2004; 3: 307-320
- Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects.Am J Respir Crit Care Med. 2005; 172: 1416-1426
- Proteomic analysis of nasal cells from cystic fibrosis patients and noncystic fibrosis control individuals: search for novel biomarkers of cystic fibrosis lung disease.Proteomics. 2006; 6: 2314-2325
- A model for random sampling and estimation of relative protein abundance in shotgun proteomics.Anal Chem. 2004; 76: 4193-4201
- Quantitative analysis of complex protein mixtures using isotope-coded affinity tags.Nat Biotechnol. 1999; 17: 994-999
- Mass spectrometric analysis of protein mixtures at low levels using cleavable 13C-isotope-coded affinity tag and multidimensional chromatography.Mol Cell Proteomics. 2003; 2: 299-314
- Protein profiling with cleavable isotope-coded affinity tag (cICAT) reagents: the yeast salinity stress response.Mol Cell Proteomics. 2003; 2: 1198-1204
- Evaluation of the acid-cleavable isotope-coded affinity tag reagents: application to camptothecin-treated cortical neurons.J Proteome Res. 2004; 3: 469-477
- Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents.Mol Cell Proteomics. 2004; 3: 1154-1169
- Shotgun proteomics using the iTRAQ isobaric tags.Brief Funct Genomic Proteomic. 2006; 5: 112-120
- Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics.Mol Cell Proteomics. 2002; 1: 376-386
- Interpretation of shotgun proteomic data: the protein inference problem.Mol Cell Proteomics. 2005; 4: 1419-1440
- Mass spectrometry-based proteomics.Nature. 2003; 422: 198-207
- Mass spectrometry and protein analysis.Science. 2006; 312: 212-217
- Large-scale protein identification using mass spectrometry.Biochim Biophys Acta. 2003; 1646: 1-10
- Multidimensional peptide separations in proteomics.Trends Biotechnol. 2002; 20: S8-S13
- Analysis of proteins and proteomes by mass spectrometry.Annu Rev Biochem. 2001; 70: 437-473
- Shotgun proteomics and biomarker discovery.Dis Markers. 2002; 18: 99-105
- Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome.J Proteome Res. 2003; 2: 43-50
- Diagnostic challenges for multiplexed protein microarrays.Drug Discov Today. 2006; 11: 1007-1011
- Development of a high-throughput automated analyzer using biochip array technology.Clin Chem. 2005; 51: 1165-1176
- Diagnostic and analytical applications of protein microarrays.Expert Rev Proteomics. 2005; 2: 41-48
- Multiplexed protein measurement: technologies and applications of protein and antibody arrays.Nat Rev Drug Discov. 2006; 5: 310-320
- Applications of antibody array platforms.Curr Opin Biotechnol. 2006; 17: 415-421
- Clinical proteomics: new trends for protein microarrays.Curr Med Chem. 2006; 13: 1831-1837
- Recent advances of protein microarrays.Curr Opin Chem Biol. 2006; 10: 4-10
- High-throughput proteomics using antibody microarrays.Expert Rev Proteomics. 2004; 1: 355-364
- An array of possibilities for the study of autoimmunity.Nature. 2005; 435: 605-611
- Protein microarrays for multiplex analysis of signal transduction pathways.Nat Med. 2004; 10: 1390-1396
- Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus.Lupus. 2004; 13: 304-311
- Protein microarrays as a discovery tool for studying protein-–protein interactions.Expert Rev Proteomics. 2005; 2: 13-26
- Serum proteomic signature for cystic fibrosis using an antibody microarray platform.Mol Genet Metab. 2006; 87: 303-310
- The dynamic range of protein expression: a challenge for proteomic research.Electrophoresis. 2000; 21: 1104-1115
- The human plasma proteome: history, character, and diagnostic prospects.Mol Cell Proteomics. 2002; 1: 845-867
- Clonal proteomics: one gene—family of proteins.Proteomics. 2002; 2: 624-631
- Multisite protein modification and intramolecular signaling.Oncogene. 2005; 24: 1653-1662
- Proteomics: new perspectives, new biomedical opportunities.Lancet. 2000; 356: 1749-1756
- Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions.Eur J Endocrinol. 2003; 149: 79-90
- Function of alternative splicing.Gene. 2005; 344: 1-20
- How prevalent is functional alternative splicing in the human genome?.Trends Genet. 2004; 20: 68-71
- Protein glycosylation: new challenges and opportunities.J Org Chem. 2005; 70: 4219-4225
- Protein glycosylation in diverse cell systems: implications for modification and analysis of recombinant proteins.Expert Rev Proteomics. 2006; 3: 345-359
- Sweet 'n' sour: the impact of differential glycosylation on T cell responses.Nat Immunol. 2002; 3: 903-910
- Glycosylation and the immune system.Science. 2001; 291: 2370-2376
- Regulation of signal transduction pathways in development by glycosylation.Curr Opin Struct Biol. 2002; 12: 593-598
- Glycosylation regulates Notch signaling.Nat Rev Mol Cell Biol. 2003; 4: 786-797
- Role of glycosylation in development.Annu Rev Biochem. 2004; 73: 491-537
- Intracellular glycosylation and development.Biochim Biophys Acta. 2002; 1573: 336-345
- Post-translational modifications in the context of therapeutic proteins.Nat Biotechnol. 2006; 24: 1241-1252
- Proteomic analysis of glycosylation: structural determination of N- and O-linked glycans by mass spectrometry.Expert Rev Proteomics. 2005; 2: 87-101
- Comparative proteomics of glycoproteins based on lectin selection and isotope coding.J Proteome Res. 2003; 2: 618-625
- The regulation of protein function by multisite phosphorylation–a 25 year update.Trends Biochem Sci. 2000; 25: 596-601
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial).J Clin Oncol. 2003; 21 ([corrected]): 2237-2246
- Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.JAMA. 2003; 290: 2149-2158
- Identification of phosphorylated proteins.Methods Mol Biol. 2006; 355: 305-316
- Phosphoproteomics toolbox: computational biology, protein chemistry and mass spectrometry.FEBS Lett. 2006; 580: 4764-4770
- Alternative splicing in disease and therapy.Nat Biotechnol. 2004; 22: 535-546
- Congenital disorders of glycosylation: a booming chapter of pediatrics.Curr Opin Pediatr. 2004; 16: 434-439
- Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.Ann N Y Acad Sci. 2005; 1043: 759-766
- Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation.Glycobiology. 2005; 15: 16R-28R
- RNA processing and human disease.Cell Mol Life Sci. 2000; 57: 235-249
- The connection between splicing and cancer.J Cell Sci. 2006; 119: 2635-2641
- Cystic fibrosis: genotypic and phenotypic variations.Annu Rev Genet. 1995; 29: 777-807
- Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML.Leukemia. 2006; 20: 1316-1319
Article info
Footnotes
Supported by Grants from the Cystic Fibrosis Foundation CFF #DUNCAN0100, CFF #HUNSUC05A0 and from the NIH U01 HL081335-01, and M01 RR00069.
Identification
Copyright
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
